Huma Therapeutics Limited and Bayer, have partnered to develop the Bayer Aspirin Heart Risk Assessment, an online tool that quickly assesses an individual's risk factors for developing cardiovascular disease (CVD) over the next 10 years. This tool can be shared with a healthcare professional as part of ongoing health management.
Huma developed the algorithm using data from the UK's Biobank which predicts long-term risk of cardiovascular disease, and the research has been validated and published in a peer-reviewed scientific journal.
Individuals can follow the user-friendly, 15-question prompts that will determine whether they are at higher, average, or lower risk of developing CVD by comparing their answers to those of the research population.
The tool was unveiled today in honour of Heart Month in the US and to underscore Bayer's legacy in CVD. The aim of the tool is to reach more than 100 million people who may be at risk of CVD across the US with actionable insights to help improve their heart and overall health. The tool aims to remind people to educate themselves about their personal risks and to have a conversation with their doctor about heart health.
Bayer is set to launch a national public awareness campaign about ongoing heart health education and risk management that will utilise this tool as a core pillar. The campaign will encourage those at elevated risk to talk to their healthcare professional about their risk profile as a proactive way to manage their health risks. Educational health information will be made available through various digital media and partner channels.
Parallely, Huma has also announced a partnership with Camden Health Partners and UCLPartners to deliver a digital-first programme aimed at identifying more people living in North Central London who are at high risk of, or who have undiagnosed, cardiovascular disease (CVD) and helping them to adopt new behaviours to help modify the condition. The programme will form a blueprint for potential national adoption.
Supported by a grant from the Small Business Research Initiative (SBRI) Healthcare, the initiative aligns with the government's review-driven plans to digitize the existing National Health Service (NHS) Health Check, making it more convenient for patients to carry out the checks at home and reduce pressure on GPs.
The digital-first programme aims to expand the Health Check system by:
Prompting individuals to complete appointments linked to the Health Check through Huma's iPLATO multi-channel engagement platform.
Moving the majority of the Health Check to a digital format on Huma's remote patient monitoring platform, reducing in-person appointment duration and thereby increasing population screening capacity.
Driving access to online, approved materials which recommend lifestyle changes in line with improving CVD status.
Providing enhanced access to face-to-face health checks for those who do not wish to use digital tools, to avoid digital exclusion.
CVD is the world's leading cause of death according to the World Health Organization. It is the single biggest condition where lives can be saved by the UK's NHS over the next decade. There are 7.6 million people living with CVD in the UK, and it is a leading cause of premature disability, mortality, and health inequalities, responsible for one in four deaths each year.
Join the HealthXL Meeting on ‘Digital Biomarkers for Mental Health Evaluation and Management’ on 16th February. Click here to Request to Join.
Click here to read the original news story.